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Background:  Vaccination  that prevents  tuberculosis  (TB)  disease,  particularly  in adolescents,  would  have
the greatest  impact  on  the  global  TB epidemic.  Safety,  reactogenicity  and immunogenicity  of  the  vac-
cine candidate  M72/AS01E was  evaluated  in  healthy,  HIV-negative  adolescents  in a TB  endemic  region,
regardless  of  Mycobacterium  tuberculosis  (M.tb)  infection  status.
Methods:  In  a phase  II, double-blind  randomized,  controlled  study  (NCT00950612),  two  doses  of
M72/AS01E or placebo  were  administered  intramuscularly,  one  month  apart.  Participants  were  followed-
up  post-vaccination,  for 6  months.  M72-speciﬁc  immunogenicity  was  evaluated  by intracellular  cytokine
staining  analysis  of  T cells  and NK  cells  by ﬂow  cytometry.
Results:  No  serious  adverse  events  were  recorded.  M72/AS01E induced  robust  T cell  and  antibody
responses,  including  antigen-dependent  NK  cell  IFN-  production.  CD4  and  CD8 T cell responses  were
sustained  at  6 months  post  vaccination.  Irrespective  of M.tb  infection  status,  vaccination  induced  a high72/AS01E frequency  of  M72-speciﬁc  CD4 T cells  expressing  multiple  combinations  of  Th1  cytokines,  and  low  level
IL-17.  We  observed  rapid  boosting  of  immune  responses  in  M.tb-infected  participants,  suggesting  natural
infection acts as  a prime  to vaccination.
Conclusions:  The  clinically  acceptable  safety  and  immunogenicity  proﬁle  of M72/AS01E in  adolescents
living  in an  area  with  high  TB burden  support  the  move  to efﬁcacy  trials.
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cases and 1.5 million deaths a year [1]. TB results in substantial per-
sonal, social, public health, and economic cost. South Africa faces
a particularly high burden of TB disease, with the second highest
annual incidence of TB cases in the world. Globally, the TB epi-
demic is compounded by the emergence of drug resistance; novel
vaccination strategies may  impact both drug sensitive and resistant
disease.Bacille Calmette-Guérin (BCG) is the only currently licensed vac-
cine against TB disease. Although BCG has been in use since 1921,
it provides highly variable and mostly poor protection against pul-
monary TB disease in adolescents and adults [1–5]. Adolescents and
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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dults with TB disease spread Mycobacterium tuberculosis (M.tb),
nd should therefore be the main target populations of novel TB
accination strategies [6].
Fourteen TB vaccine candidates are currently in clinical testing
7]. Most novel TB vaccine candidates aim to boost or modulate
re-existing T cell responses against M.tb. M72/AS01E, one such
accine candidate, is a recombinant fusion protein (M72) derived
rom Mtb32 and Mtb39, adjuvanted with AS01E[8]. M72/AS01E has
hown promise in multiple Phase I and IIa clinical trials in adults
9–14], including M.tb-infected persons living in a high TB bur-
en setting. In these studies, the vaccine had a clinically acceptable
afety proﬁle and induces high magnitude M72-speciﬁc CD4 T cell
esponses, including a complex pattern of Th1 cytokines. However,
he vaccine has not been evaluated in adolescents, a major target
opulation for novel vaccination strategies. The aim of this study
as to assess safety, reactogenicity and immunogenicity of two
oses of M72/AS01E vaccination in healthy, Human Immunodeﬁ-
iency Virus (HIV) uninfected adolescents living in a TB endemic
etting.
. Methods
.1. Study design
This Phase II, double-blind randomized, controlled trial was
pproved by the University of Cape Town Health Sciences Human
esearch Ethics Committee (ClinicalTrials.gov, NCT00950612), and
onducted in accordance with the Helsinki Declaration and Good
linical Practices. Informed consent was obtained from the legal
uardians and assent from the participants prior to screening.
.2. Participants and vaccination
Greater detail of all procedures, including the vaccine, assays
nd statistical analysis, can be found in the supplementary mate-
ial. Brieﬂy, we aimed to enroll 60 adolescents aged 13–17 years
rom the Cape Town region of South Africa if they were healthy,
IV-negative, with no previous or current TB disease, and regard-
ess of M.tb infection status (determined by QuantiFERON TB Gold
n-Tube test (QFT)). Screening procedures included physical exam-
nation, chest X-ray, blood tests for hematology and biochemistry
nd a pregnancy test in females. Following blinded randomization,
0 participants were allocated to receive 2 doses of M72/AS01E
10 g M72  adjuvanted with AS01E, an adjuvant system containing
5 g 3-O-desacyl-4’-monophosphoryl lipid A (MPL), 25 g QS-21
timulon® [Quillaja saponaria Molina, fraction 21; licensed by GSK
rom Antigenics Inc., a wholly owned subsidiary of Agenus Inc.,
 Delaware, USA corporation] and liposome) and 20 to receive 2
oses of placebo (saline), on study days 0 and 30, administered
ntramuscularly.
.3. Safety and reactogenicity evaluation
Injection site reactions, solicited and unsolicited systemic
dverse events (AEs), and safety blood abnormalities were evalu-
ted by diary card completion, physical examination and laboratory
esting. Follow up clinic visits were performed 1 and 7 days after
ach vaccination, and on days 60 and 210 after the ﬁrst vaccina-
ion.
.4. Antibody ELISAOn study days 0, 30, 60 and 210, total anti-M72 IgG was mea-
ured in serially-diluted serum by ELISA, as previously described
10,14].ne 33 (2015) 4025–4034
2.5. T cell intracellular cytokine staining assay
Two intracellular cytokine staining (ICS) assays were completed
on samples collected on study days 0, 7, 30, 37, 60, and 210. First,
whole blood was incubated with an M72  peptide pool, or with
recombinant M72  fusion protein, as previously described [15,16].
Expression of IFN-, IL-2, TNF-, IL-17, Ki67 and PD-1 was deter-
mined in CD4 and CD8 T cells. Second, isolated and stored PBMC
were later thawed and incubated with the M72  peptide pool, as
previously described [10,17]. Expression of CD40L, IFN-, IL-2 and
TNF- were determined in CD4 and CD8 T cells. Cells were acquired
on a LSR II ﬂow cytometer (BD Biosciences).
2.6. NK cell intracellular cytokine staining assay
CD56+CD16+/− NK cell expression of IFN- and CD69 was  mea-
sured following PBMC incubation with an M72  peptide pool, using
an adapted ICS as previously described [18,19].
2.7. Data analysis
Frequency of AEs was described per number of administered
doses, by type (injection site, systemic, laboratory), and by sever-
ity, seriousness and causality. Frequency and pattern of expression
of different markers were outcomes of the ICS; data were ana-
lyzed using FlowJo software (TreeStar). Speciﬁc responses were
calculated by subtraction of response frequencies in unstimulated
samples from stimulated samples. Antibody results were described
as geometric mean concentrations (GMC); a response was deﬁned
as >2.8 ELISA units/mL. Statistical comparisons between groups and
time points were assessed with nonparametric tests, using Graph-
Pad Prism 6.0d (GraphPad Software). Analysis were per protocol
unless otherwise indicated.
3. Results
3.1. Participants
Sixty healthy, HIV-negative adolescents (median age 15.0 years,
interquartile range – IQR – 14.1–16.3) were enrolled (Table 1). All
participants had documented evidence of BCG vaccination or BCG
scar. On Day 0 and Day 30, forty participants received M72/AS01E
vaccine, and twenty received placebo. Demographic characteristics
and reasons for exclusion did not differ between groups at baseline
(Table 1 and Fig. S1).
3.2. M72/AS01E had a clinically acceptable safety proﬁle
No participant experienced a serious adverse event (SAE) or
withdrew due to an AE. AEs were reported in the 7 day post-
vaccination period after 93.8% of all doses in the M72/AS01E group
and after 57.9% of all doses in the placebo group (Table S1). In the
M72/AS01E group, local AEs were reported after 90% of doses and
general AEs after 75% of doses. In the placebo group, local AEs were
reported after 26.3% of doses and general AEs after 44.7% of doses.
92.5% of M72/AS01E recipients had AEs after dose 1 and 95% after
dose 2; these frequencies were 61.1% and 55% in placebo recipients,
respectively.
The most common M72/AS01E associated local AE was pain,
after 90% of doses, followed by swelling and redness, after 34%
and 21% of doses, respectively (Table 2). Pain occurred after 21%
of placebo doses, and swelling and redness each after 5% of doses.Headache, fever, and fatigue were the most frequently reported
systemic AEs among M72/AS01E recipients, after 54%, 45%, and 39%
of doses, respectively, compared to 16%, 5%, 13% in the placebo
group (Table 2).
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Table  1
Demographic characteristics of enrolled participants.
M72/AS01E (n = 40) Placebo (n = 20) Overall (n = 60)
Male, n (%) 22 (55.0) 9 (45.0) 31 (51.7)
Median  age in years (range, IQRa) 15.0 (13–17, 14–16) 14.5 (14–17, 14–15) 15.0 (13–17, 14–16)
Race,  n (%)
Black 11 (27.5%) 6 (30.0%) 17 (28.3%)
White  3 (7.5%) 1 (5.0%) 4 (6.7%)
Mixed  race 26 (65.0%) 13 (65.0%) 39 (65.0%)
QuantiFERON status at baseline, n (%)
Negative 22 (55.0%) 10 (50.0%) 32 (53.3%)
Positive  18 (45.0%) 10 (50.0%) 28 (46.7%)
n
s
a
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F
Aa IQR, Interquartile range.
 (%) = number (percentage) of participants enrolled.
Unsolicited AEs 30 days post-vaccination, including abnormal
afety laboratory ﬁndings, were infrequent, occurring after 15% of
ll doses in the M72/AS01E group, and 15% in placebo group (Table
2).
.3. M.tb infection might be associated with a higher frequency of
dverse events
As expected for an endemic region, 45% of M72/AS01E vacci-
ees and 50% of placebo recipients were QFT-positive at baseline
Table 1) [20]. Post hoc analyses showed that the frequency of
njection site reactions and unsolicited symptoms were similar
etween participants who were QFT-positive and -negative at
nrollment (data not shown). Some solicited general symptoms
fever, headache and gastro-intestinal symptoms) occurred more
requently in QFT-positive participants receiving M72/AS01E (Table
3).
able 2
requency of solicited local adverse events (AEs) and general AEs reported during the 7-da
Es  considered related and not-related to vaccination.
M72/AS01E
(N = 80)b 95% CId
Local AE
Pain
All 72 (90) 81.2–95.6
Grade  3c 10 (12.5) 6.2–21.8
Redness
All  17 (21.3) 12.9–31.8
Grade  3c 1 (1.3) 0.0–6.8 
Swelling
All  27 (33.8) 23.6–45.2
Grade  3c 0 (0.0) 0.0–4.5 
General AE
Fatigue
All 31 (38.8) 28.1–50.3
Grade  3 3 (3.8) 0.8–10.6
Gastrointestinal symptoms
All 22 (27.5) 18.1–38.6
Grade  3 1 (1.3) 0.0–6.8 
Headache
All  43 (53.8) 42.2–65.0
Grade  3 9 (11.3) 5.3–20.3
Malaise
All  19 (23.8) 14.9–34.6
Grade  3 3 (3.8) 0.8–10.6
Myalgia
All  9 (11.3) 5.3–20.3
Grade  3 2 (2.5) 0.3–8.7 
Fever
All  36 (45) 33.8–56.5
Grade  3c 4 (5.0) 1.4–12.3
a n (%) = number (percentage) of doses followed by at least one type of AE.
b N = number of documented doses (2 dose schedule per protocol. Two  subjects did not
c Grade 3 deﬁned as >50 mm (redness, swelling) or symptom severe enough to limit no
d Exact 95% conﬁdence interval, lower limit and upper limit range of % proportion.3.4. M72/AS01E induces a speciﬁc CD4 T cell response, which is
boosted and sustained by a second vaccine dose:
T cell responses to vaccination were measured with a whole
blood ICS assay and ﬂow cytometry (Fig. S2). The highest observed
frequencies of M72-speciﬁc CD4 T cells producing IFN-, TNF-,
IL-2 and/or IL-17 occurred 7 days post-vaccination (Fig. 1A), with
signiﬁcant boosting after the second dose. M72-speciﬁc CD4 T cell
frequencies remained higher than pre-vaccination levels at all the
time points following vaccination (p < 0.0001, Day 210 vs. pre-
vaccination).
In vaccinees, M72-speciﬁc CD4 T cells expressed multiple com-
binations of IFN-, IL-2, TNF- and/or IL-17 (Fig. 1B): 11 distinct
subsets maintained higher cytokine expression at Day 210, com-
pared with pre-vaccination. Cytokine combinations expressed at
greatest frequency were IFN-/IL-2/TNF- together, TNF-/IFN-
together, or TNF-/IL-2 together. IL-17-producing CD4 T cells were
y follow-up periods following ﬁrst or second vaccination n (%).a General AE include
Placebo
(N = 38)b 95% CId
 8 (21.1) 9.6–37.3
 0 (0.0) 0–9.3
 2 (5.3) 0.6–17.7
0 (0.0) 0.0–9.3
 2 (5.3) 0.6–17.7
0 (0.0) 0.0–9.3
 5 (13.2) 4.4–28.1
 0 (0.0) 0.0–9.3
 5 (13.2) 4.4–28.1
2 (5.3) 0.6–17.7
 6 (15.8) 6.0–31.3
 0 (0.0) 0.0–9.3
 3 (7.9) 1.7–21.4
 0 (0.0) 0.0–9.3
 3 (7.9) 1.7–21.4
0 (0.0) 0.0–9.3
 2 (5.3) 0.6–17.7
 0 (0.0) 0.0–9.3
 return diary cards after both injections and are not included in this table.
rmal daily activity (pain), or a temperature >39.5 ◦C (fever).
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Fig. 1. M72/AS01E induces a robust CD4 T cell response that is boosted with a second vaccination. Longitudinal CD4 T cell responses to pooled M72 peptides in whole blood
(A  and B) and cryopreserved PBMC (C) from individual participants. (A) Total cytokine responses were calculated as the frequencies of CD4 T cells expressing any of IFN-,
IL-2,  TNF- and/or IL-17. Each line represents a different individual in either the M72/AS01E vaccinated (n = 40, in red) or placebo vaccinated group (n = 19, in blue). Arrows
represent the time of vaccination. Results are shown after background subtraction of frequencies of cytokine-expressing CD4 T cells in the unstimulated negative control
sample.  Wilcoxon matched pairs signed rank test was used to compare frequencies of M72-speciﬁc total cytokine response between two time points. Wilcoxon matched
pairs  signed rank test p values are shown, compared to pre-vaccination time point. (B) Vaccination induced a complex proﬁle of cytokine expression and multiple distinct
subsets of CD4 T cell responses. Frequencies of M72-speciﬁc CD4 T cells expressing IFN-, IL-2, TNF- and IL-17 were measured by ICS assay after 12 h stimulation of whole
blood  with M72  peptide pools. For each plot, only the M72/AS01E vaccinated participants are shown. The median is represented by the horizontal line, the interquartile
range  by the box and the range by the whiskers. Durability of response of each subset of CD4 T cell population was measured by Wilcoxon matched-pairs signed rank test
comparing Day 210 to pre-vaccination responses; only values <0.05 are shown. Representative ﬂow cytometry plots and gating strategy are shown in Supplementary Fig. S2.
(C)  Frequencies of CD4 T cells expressing IL-2, TNF-, IFN- and CD40L in response to M72  peptide pool stimulation measured in cryopreserved PBMC by ICS. For B and C, only
the  M72/AS01E vaccinated participants are shown. Results are shown after background subtraction of cytokine production in the unstimulated control. (For interpretation
of  the references to color in this ﬁgure legend, the reader is referred to the web  version of this article.)
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etected with a peak measured response 7 days after a second
accine dose (Fig. S3).
The pattern and kinetics of M72-speciﬁc Th1 cytokine produc-
ion was independently conﬁrmed by PBMC ICS (Fig. 1C). With the
xception of CD40L expression, not assessed in whole blood, lower
esponses were observed in PBMC (Fig. 1C).
The peak response of the cell cycling marker Ki67 was at 7 days
fter each vaccination (Fig. S4A); a large proportion of Ki67+ cells
id not express any of the classical Th1 or Th17 cytokines, and vice
ersa (Fig. S4B). Expression of PD-1, a negative regulator of acti-
ated T cells, was elevated on M72-speciﬁc CD4 T cells at all time
oints post-vaccination, with kinetics similar to those of cytokine
xpression (Fig. S5A).
.5. M72/AS01E induces a sustained CD8 T cell response
Kinetics of the M72-induced CD8 T cell response was  similar to
hat of CD4 T cells, but of lower magnitude and greater individ-
al variability after both doses of vaccine (Fig. 2A). In the majority
f vaccinated participants, vaccination boosted detectable CD8 T
ells frequencies above pre-vaccination levels, at all time points
p < 0.0001, Day 210 vs. pre-vaccination). M72-speciﬁc CD8 T cell
esponses in placebo recipients did not increase signiﬁcantly over
ime.
Overall, M72-speciﬁc CD8 T cell responses detected in cryopres-
rved PBMC were low compared to whole blood (Fig. 2B and C),
s seen previously [9,10,12]. M72/AS01E induced predominantly
FN- single-positive CD8 T cells, and, in whole blood, TNF-
ingle-positive CD8 T cells. In whole blood, Day 210 frequen-
ies were elevated above baseline for IFN- single-positive
p < 0.0001), TNF- single-positive (p = 0.0004) and IFN-+TNF-+
ubsets (p = 0.0394).
PD-1 expression on M72-speciﬁc IFN-+ CD8 T cells was low at
ll time points post-vaccination (Fig. S5B). Expression patterns of
i67 were similar to those observed for CD4 T cells (Fig. S4A and
).
.6. Vaccination with M72/AS01E activates NK cells
The effect of M72/AS01E on NK cell responses immediately
ost-vaccination was measured in a subset of participants PBMC
M72/AS01E: n = 27; placebo: n = 15) post hoc. Recent observa-
ions suggest that CD4 T cells, through IL-2, can activate NK cells
o produce IFN- [18,19,21]. By stimulating cryopreserved PBMC
ith M72  peptide pool, we observed IFN- production by both
D56+CD16− and CD56+CD16+ subsets of NK cells (Fig. 3A and B).
urther, activated NK cells co-expressing CD69 and IFN- were
ncreased 7 days after each vaccination, compared with placebo.
t day 37, frequencies of IL-2-expressing M72-speciﬁc CD4 T cells
orrelated with frequencies of IFN--expressing NK cell subsets
Fig. 3C and D).
.7. M72  induces an antibody response
Anti-M72 IgG antibody response against the recombinant M72
rotein was measured in serum by ELISA. Prior to vaccina-
ion, all participants except one in the M72/AS01E group were
eronegative. After 2 vaccine doses, all participants had converted
o seropositivity; 2 placebo recipients had detectable but low titer
nti-M72 IgG. By Day 210, M72-speciﬁc IgG was  still detectable
n all vaccinees (p < 0.0001 Day 210 vs. pre-vaccination) and in 1
lacebo recipient (Fig. 4).e 33 (2015) 4025–4034 4029
3.8. M72 induces a higher response in individuals already
exposed to M.tb
To determine the effects of M.tb infection on vaccination-
induced immune responses, we stratiﬁed participants according
to QFT status (Table 1). Baseline total cytokine responses of M72-
speciﬁc CD4 and CD8 T cells were uniformly low in both groups.
M72-speciﬁc T cell responses following vaccine priming were much
higher in M.tb-infected individuals compared with M.tb-uninfected
individuals (Fig. 5A); in the latter group, the speciﬁc responses were
more prominent after the second dose. There was  a strong corre-
lation between M72-speciﬁc T cell cytokine production and IFN-
detected by QFT (Fig. S6).
In whole blood assays, M72-speciﬁc CD4 T cell responses in
M.tb-uninfected persons never reached the magnitude of those
achieved in M.tb-infected persons; however, in PBMC, the response
was equivalent at Day 60 and Day 210 (data not shown).
As for CD4 T cells, similar kinetics were observed for CD8 T
cell responses in the M.tb-infected group, except that lesser boost-
ing was observed following the second vaccination (Fig. 5A). After
boosting, CD8 T cell responses were similar in both groups, and
maintained up to Day 210 at levels signiﬁcantly higher than those
observed pre-vaccination.
Proportions of M72-speciﬁc CD4 T cells expressing ≥3 cytokines
together were higher in M.tb-infected individuals on Day 30, 37 and
210, compared with M.tb-uninfected individuals (Fig. 5B). In con-
trast, M.tb-infected persons showed lower proportions of induced
CD8 T cells expressing ≥2 cytokines at Day 60 and 210, compared
with uninfected individuals.
Ki67 expression on both CD4 and CD8 T cells showed similar
kinetics 7 days post-vaccination (Fig. S4C and E). PD-1 expres-
sion on CD4 T cells was higher in M.tb-uninfected participants
at all time points post-vaccination (Fig. S5C). No difference was
seen in PD-1 expression on CD8 T cells among the groups
(Fig S5D).
M.tb infection also resulted in a much greater boost of IFN-
production by both CD16− and CD16+ activated NK cells in vac-
cinees (Fig. 5C), and strong association with IL-2 production by
M72-speciﬁc CD4 T cells (Fig. 5D). The proportion of participants
with high frequencies of both IL-2-producing CD4 T cells and IFN-
-producing NK cells increased with vaccinations. By Day 37, all
M.tb-infected participants with high frequencies of IL-2-producing
CD4 T cells also had increased proportions of IFN--producing
CD56+CD16− NK cells, and 8 of 10 M.tb-infected participants
had high proportions of IFN--producing CD56+CD16+NK cells. A
similar, although less striking association was also seen in M.tb-
uninfected participants.
M.tb-infected adolescents responded to the ﬁrst vaccination
with higher anti-M72 IgG antibody titers at Day  30, compared
to M.tb-uninfected adolescents, but not at the other time points
(Fig. 5E).
4. Discussion
In this Phase II trial, conducted in a TB endemic setting, we
showed that two doses of M72/AS01E candidate vaccine, deliv-
ered intramuscularly 30 days apart to healthy, HIV-uninfected
adolescents, had a clinically acceptable safety and reactogeni-
city proﬁle. The vaccine was  immunogenic and induced sustained
antigen-speciﬁc CD4 and CD8 T cell and IgG responses up to 6
months post last vaccination. These ﬁndings were independent of
prior M.tb infection, although natural priming with M.tb resulted in
faster and quantitatively higher whole blood immune responses to
M72/AS01E. These ﬁndings complement safety and immunological
observations in trials conducted in M.tb-infected adults in South
4030 A. Penn-Nicholson et al. / Vaccine 33 (2015) 4025–4034
Fig. 2. M72/AS01E induces a sustained CD8 T cell response. Longitudinal CD8 T cell responses to pooled M72  peptides in whole blood (A and B) and cryopreserved PBMC
(C)  from individual participants. (A) Total cytokine responses were calculated as the frequencies of CD8 T cells expressing any of IFN-, IL-2, TNF- and/or IL-17. Each line
represents a different individual in either the M72/AS01E vaccinated (n = 40, red) or placebo-vaccinated group (n = 19, blue). Arrows represent the time of vaccination. Results
are  shown after background subtraction of frequencies of cytokine-expressing CD8 T cells in the unstimulated negative control sample. Wilcoxon matched pairs signed
rank  test was  used to compare frequency of M72-speciﬁc total cytokine response between two time points. Wilcoxon matched pairs signed rank test p values are shown
after  adjustment for multiple comparisons, compared to pre-vaccination time point. Friedman test was used to calculate signiﬁcant differences across time. (B) Frequencies
of  M72-speciﬁc CD8 T cells expressing IFN-, IL-2, TNF- and IL-17 measured by ICS assay after stimulation of whole blood with M72 peptide pools. For each plot, only
M72/AS01E vaccinated participants are shown. The median, interquartile range and range are shown. Durability of response of each CD8 T cell subset was measured by
Wilcoxon matched-pairs signed rank test comparing Day 210 to pre-vaccination responses; only values <0.05 are shown. (C) Frequencies of CD8 T cells expressing IL-2,
TNF-,  IFN- and CD40L in response to M72  peptide pool stimulation measured in cryopreserved PBMC by ICS. For B and C, only the M72/AS01E vaccinated participants are
shown.  Results are shown after background subtraction of cytokine production in the unstimulated control. No subsets showed any signiﬁcance in expression between Day
0  and Day 210 in the PBMC assay when performing Wilcoxon matched pairs signed rank test. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web  version of this article.)
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frica [14] and the Philippines [13], and M.tb-uninfected adults in
urope and the USA [9–12].
M72/AS01E appeared well tolerated, although a higher fre-
uency of mild to moderate local AEs and severe pain at injection
ite was reported in the vaccinated, compared to the placebo group.
he systemic AE proﬁle was analogous to a ﬂu-like syndrome
n the ﬁrst 24 h post-vaccination. AEs were typically transient
nd resolved within 7 days. Certain solicited general symptoms
ccurred more frequently in M72/AS01E than in placebo recipients
ho were M.tb-infected at enrollment, compared with uninfected
accinees. The relatively small sample sizes in these early phase
tudies preclude deﬁnitive conclusions to be drawn about the safety
nd immunogenicity results.ellow squares) and Day 37 (blue triangles). (For interpretation of the references to
In our experience, magnitudes of the total M72-speciﬁc CD4 T
cell response induced by vaccination are among the highest seen
in recent literature when compared with responses in adolescents
and adults induced by two viral vectored vaccines, MVA85A and
Aeras-402, in the same whole blood assay using different M.tb anti-
gens for stimulation (Ag85A, Ag85B, and TB10.4) [22–24]. In the
absence of immune correlates of protection, we hypothesize that
both magnitude and quality of cellular immune responses may  be
important components of protective immunity. M72/AS01E vac-
cination induced a potent and durable M72-speciﬁc CD4 T cell
response, with frequencies of cells expressing ≥3 cytokines higher
at Day 210 than pre-vaccination. In animal models, multifunctional
CD4 T cells have correlated with protection against M.tb challenge
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nd other pathogens [25–31], although the role of cytokine co-
xpression in protection of humans against TB remains unclear
22,32,33]. For example, although low frequencies of multifunc-
ional CD4 T cells expressing IFN-, IL-2, TNF- and IL-17 were
nduced by MVA85A, the vaccine failed to improve on BCG-induced
rotective immunity against TB disease in infants [23,32]. Fur-
hermore, frequencies of multifunctional BCG-speciﬁc CD4 T cell
esponses did not correlate with risk of TB disease in infants [33].
evertheless, CD4 T cells, and TNF- and IFN- cytokine produc-
ion are considered critical for control of M.tb infection in humans
34–39].
Vaccination induced a durable M72-speciﬁc CD8 T cell response
n whole blood. CD8 T cells may  contribute to clearance of M.tb-
nfected cells [40,41]. Although CD8 responses were moderate in
agnitude compared to CD4 T cells, vaccination induced signiﬁ-
antly higher frequencies of IFN-+, TNF-+, and IFN-+TNF-+ CD8
 cell subsets at Day 210, compared to pre-vaccination. Notably,
he second vaccine dose appeared to have little, if any, boosting
ffect on M72-speciﬁc CD8 T cell responses in adolescents already
.tb-infected, but was necessary to boost responses in uninfected
articipants to equivalent levels.
Here, we show an association between IL-2-producing M72-
peciﬁc CD4 T cells and IFN--producing NK cells, suggesting that
K cells might act as effectors of acquired immune responses
18,21]. This NK cell recall response to peptide stimulation, iden-
iﬁed in malaria, rabies and HIV-1 vaccination [18,19,21,42], may
lay an important role in vaccination strategies and allow us to
urther interrogate the host immune response to M.tb vaccination
eyond classical Th1 sources of IFN- [18,19,43,44]. The CD4 T cell-
ssociated NK cell responses detected after M72/AS01E vaccination
uggest that NK cells might act as “effectors of acquired immune
esponses” [18,21]. The link between CD4 T cell responses, NK cell
ctivation and QFT status shown here is consistent with the model
roposed by Riley and others [18,21,43,44] and could bring fur-
her understanding into the mode of action of M72/AS01E. Clearly,
urther work is needed to elucidate the precise mechanisms that
ink CD4 T cell responses and NK cell activation and the role of
re-existing memory in this pathway.
Overall, our data indicate that M72/AS01E vaccination has an
cceptable clinical safety and reactogenicity proﬁle and induces
otent and sustained CD4 and CD8 T cell responses, and CD4 T
ell dependent IFN- recall responses in NK cells, in both M.tb-
nfected and uninfected healthy adolescents from a TB endemic
rea. However, different kinetics of immune responses observed
n M.tb-infected and uninfected participants suggests that, in the
ontext of M.tb vaccination, vaccine “priming” could modulate pre-
xisting immune and epitope recognition already present in an
.tb-infected and antigen exposed population. It raises important
mplications for effective approaches of vaccination to enhance
rotective immunity or prevent recurrent TB in high burden sett-
ngs. The clinically acceptable safety and reactogenicity proﬁle,
ombined with the potent and sustained T cell responses, and NK
ecall responses induced by vaccination, suggests that M72/AS01E
s a good candidate to advance into efﬁcacy trials in this key target
opulation.
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